Abstract
Surgical reconstruction of the right ventricular outflow tract-The clock is still ticking.
Highlights
The optimal device for heart valve replacement is yet to be developed
The No‐React® is just one of several different treatments that bioprosthesis producers have developed over the last few decades; all of them released with promises of improved durability, freedom from structural deterioration, and infection
The study by Selcuk et al is the first to focus on the use of the BioIntegral Biopulmonic ConduitTM on pediatric patients
Summary
The optimal device for heart valve replacement is yet to be developed. If this is certainly true for adult patients with acquired pathologies, the need for better materials is even more pressing in the setting of congenital heart disease, where any valve replacement activates a ticking clock towards the procedure. In this issue of the Journal of Cardiac Surgery, Selcuk et al.[1] report their single‐center experience with the BioIntegral Biopulmonic ConduitTM, implanted as a right ventricle‐to‐pulmonary artery conduit in 48 pediatric patients over a period of 13 months.[1] This is a stentless porcine heart valve covered with a 10‐cm long porcine pericardial sleeve, and it is available in relatively small sizes (starting from 15 mm).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
